Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radial Approach to Angioplasty Gaining Momentum

Executive Summary

If technology changes and clinical outcomes assert their influence over standard protocols, an increasing number of Americans patients will undergo coronary angioplasty through the radial artery in their wrist, not the femoral artery in their groin. As studies are beginning to portray more clearly, those patients are likely to be more comfortable postprocedure, exhibit less bleeding, and recover more quickly than patients treated treated with the traditional femoral approach.

You may also be interested in...



Interest In Transradial PCI Grows In U.S. But Barriers Remain

The standing-room-only crowd of physicians that packed a meeting room at the recent Transcatheter Cardiovascular Therapeutics conference in San Francisco to hear presentations on transradial percutaneous coronary interventions suggests interest in the technique is growing in the U.S

SK Bioscience First To Line In Korea COVID Vaccine Race

SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.

Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?

Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT035336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel